Maxim Group Maintains Azitra(AZTR.US) With Buy Rating
Maxim Group Maintains Azitra(AZTR.US) With Buy Rating
Maxim Group Maintains Azitra(AZTR.US) With Buy Rating, Maintains Target Price $3
Promising Prospects for Azitra Inc: Buy Rating Supported by Advancements in ATR-12 and ATR-04 Programs
Maxim Group Maintains Azitra(AZTR.US) With Buy Rating, Maintains Target Price $3
Maxim Group Maintains Azitra(AZTR.US) With Buy Rating, Maintains Target Price $3
Maxim Group Maintains Azitra(AZTR.US) With Buy Rating, Maintains Target Price $3
Buy Rating Justified by Azitra Inc's Advances in Rare Skin Disease Treatments and Financial Stability
Maxim Group Maintains Azitra(AZTR.US) With Buy Rating, Maintains Target Price $3
Azitra Inc (AZTR) Receives a Buy From Maxim Group
Maxim Group Maintains Azitra(AZTR.US) With Buy Rating, Announces Target Price $3
McCarthy's Buy Rating on Azitra Inc: Strong Pipeline and Strategic Financial Positioning
Maxim Group Maintains Azitra(AZTR.US) With Buy Rating
Optimistic Outlook Justifies Buy Rating for Azitra Inc Amidst Promising Product Development and Strategic Partnerships
Buy Rating Endorsed for Azitra Inc. on Strong Pipeline and Financial Stability
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS), Azitra Inc (AZTR) and Dexcom (DXCM)